Cardiology

Your Article Summary

See Latest Articles

Randomized comparison between tirofiban and abciximab to promote complete ST-resolution in primary angioplasty: results of the facilitated angioplasty with tirofiban or abciximab (FATA) in ST-elevation myocardial infarction trial
European Heart Journal, 10/30/08

Marzocchi A et al. – Findings failed to show equivalence of high-dose bolus (HDB) tirofiban and abciximab as adjunctive therapy to primary percutaneous coronary intervention (PPCI)

• Prospective, multicenter, open-label trial (Facilitated Angioplasty with Tirofiban or Abciximab [FATA] trial) of the equivalence of HDB tirofiban vs abciximab during PPCI in terms of ST-segment resolution (STR)
• Subjects: 692 pts with ST-segment elevation myocardial infarction (STEMI) undergoing PPCI
• Randomization 1:1 to receive abciximab (341 pts) or HDB tirofiban (351)
• Primary endpoint: rate of complete (≥70%) STR 90 min after first balloon inflation
• Evaluation of 30-day incidence of major bleedings, death, re-infarction and new revascularizations

• Baseline characteristics of both groups well-balanced, except previous MI rates: tirofiban 6% vs abciximab 2.6%
• Procedure successful in 96.7% of abciximab and 96.6% of tirofiban pts
• Complete STR in 67.05% of tirofiban and 70.45% of abciximab group
• Rates of secondary endpoints similar between groups

Today in Interventional...keeping you current

Receive free subspecialty "5-minute updates" via email

Antithrombotic therapy and outcomes of patients with atrial fibrillation following primary percutaneous coronary intervention: results from the APEX-AMI trial
European Heart Journal, 06/09/09

Safety and efficacy of drug-eluting and bare metal stents. Comprehensive meta-analysis of randomized trials and observational studies
Circulation, 06/17/09

Statins and their use in preventing carotid disease
Current Atherosclerosis Reports, 06/22/09

See All of Interventional